Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022

NEXT STORY
Adagio Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PREV STORY
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

author_avatar
NASDAQ Market News

GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

author_avatar
NASDAQ Market News

Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual conferences

  NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 ...

author_avatar
NASDAQ Market News